The Defender Children’s Health Defense News and Views
Close menu
Close menu

You must be a CHD Insider to save this article Sign Up

Already an Insider? Log in

August 2, 2024 Health Conditions

Big Pharma News Watch

Incidence of 17 Cancers on the Rise in Younger Generations, Major New Study Says + More

The Defender’s Big Pharma Watch delivers the latest headlines related to pharmaceutical companies and their products, including vaccines, drugs, and medical devices and treatments. The views expressed in the below excerpts from other news sources do not necessarily reflect the views of The Defender. Our goal is to provide readers with breaking news that affects human health and the environment.

Incidence of 17 Cancers on the Rise in Younger Generations, Major New Study Says

ABC News reported:

Gen X and Millennials in the U.S. are at greater risk for 17 cancers than were previous generations, a major new study revealed.

Researchers at the American Cancer Society analyzed data from millions of people born between 1920 and 1990 who were diagnosed with 34 common types of cancer between 2000 and 2019. They also reviewed death records from the same period.

The cancers on the rise included two types of stomach cancer, small intestine cancer, estrogen receptor positive breast cancer, ovarian, liver, bile duct and colorectal cancer, uterine and testicular cancer, gall bladder, kidney and pancreatic cancer, and two types of blood cancer: myeloma and leukemia.

COVID-19 Vaccination May Increase Risk for Urinary Tract Symptoms

MedicalXPress reported:

COVID-19 vaccination seems to have some side effects on the lower urinary tract and overactive bladder in younger adults, according to a study published online June 24 in Frontiers in Medicine.

Marta de-la-Plaza-San-Frutos, from Universidad Europea de Madrid in Spain, and colleagues examined potential side effects of COVID-19 vaccination on the urinary tract among 1,563 individuals (74.7% women and 27.3% men), aged 18 to 45 years, who completed an online survey.

“Based on the results obtained in this study, monitoring and addressing urinary tract side effects of COVID-19 vaccination are important for vaccination programs to include the systematic collection of urinary tract side effect data, which will allow for ongoing evaluation of vaccine safety and efficacy,” the authors write. “Health care professionals should be alert to the possibility of patients experiencing urinary tract symptoms following COVID-19 vaccination.”

Canadian Health Officials Call for Only One Gardasil HPV Vaccine Injection for Children

About Lawsuits reported:

Amid continuing concerns about the side effects of Gardasil and a number of lawsuits being pursued in the U.S., involving allegations that the HPV vaccine caused severe and debilitating autoimmune disorders, Canadian health officials now indicate that children only need one dose to help prevent infections and cervical cancer.

Gardasil was introduced in 2006, as the first vaccination against the development of human papillomavirus, which can be sexually transmitted and lead to the later development of cervical cancer. The injection has been widely used among both young girls and boys, before sexual activity, typically involving a series of two or three shots several months apart.

Last week, Canada’s National Advisory Committee on Immunization (NACI) issued new guidelines on HPV immunization, indicating that multiple doses of the vaccine are only needed for patients who are 21 years of age and older. Those between the ages of 9 and 20 only need to receive one injection to be adequately protected from the human papillomavirus and decrease their risks of cervical cancer, the committee determined.

Merck Shares Slide as Gardasil Sales Drop in China

Biopharma Dive reported:

Merck shares dropped almost 10% Tuesday after the company disclosed a “significant step down” in shipments of its Gardasil vaccine to providers in China during the second quarter.

Gardasil, designed to prevent infection with human papillomavirus, is Merck’s second-best selling medicine, after the blockbuster cancer drug Keytruda.

In the second quarter, overall sales of the Gardasil franchise reached $2.48 billion, little changed from the year-earlier period. Analysts had expected revenue of about $2.7 billion for the product in the quarter, according to Leerink Partners.

Suggest A Correction

Share Options

Close menu

Republish Article

Please use the HTML above to republish this article. It is pre-formatted to follow our republication guidelines. Among other things, these require that the article not be edited; that the author’s byline is included; and that The Defender is clearly credited as the original source.

Please visit our full guidelines for more information. By republishing this article, you agree to these terms.

Woman drinking coffee looking at phone

Join hundreds of thousands of subscribers who rely on The Defender for their daily dose of critical analysis and accurate, nonpartisan reporting on Big Pharma, Big Food, Big Chemical, Big Energy, and Big Tech and
their impact on children’s health and the environment.

  • This field is for validation purposes and should be left unchanged.
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
    MM slash DD slash YYYY
  • This field is hidden when viewing the form